Malignant : How Bad Policy and Bad Evidence Harm People with Cancer.
Prasad, Vinayak K.
Malignant : How Bad Policy and Bad Evidence Harm People with Cancer. - 1st ed. - 1 online resource (304 pages)
Cover -- Half Title -- Title -- Copyright -- Dedication -- Contents -- Acknowledgments -- Introduction -- PART I CANCER DRUGS: The Outcomes They Improve and at What Price -- 1 The Basics of Cancer Drugs: Cost, Benefit, Value -- 2 Surrogate Endpoints in Cancer: What Are They and Where Are They Used? -- 3 The Use and Misuse of Surrogate Endpoints for Drug Approvals -- 4 How High Prices Harm Patients and Society -- PART II SOCIETAL FORCES THAT DISTORT CANCER MEDICINE -- 5 Hype, Spin, and the Unbridled Enthusiasm That Distorts Cancer Medicine -- 6 Financial Conflict of Interest -- 7 The Harms of Financial Conflicts and How to Rehabilitate Medicine -- 8 Will Precision Oncology Save Us? -- PART III HOW TO INTERPRET CANCER EVIDENCE AND TRIALS -- 9 Study Design 201 -- 10 Principles of Oncology Practice -- 11 Important Trials in Oncology -- 12 Global Oncology -- PART IV SOLUTIONS -- 13 How Should Cancer Drug Development Proceed -- 14 What Can Three Federal Agencies Do Tomorrow? -- 15 What Can People with Cancer Do? -- 16 What Can Students, Residents, and Fellows -- Epilogue: The Hallmarks of Successful Cancer Policy -- Glossary -- References -- Index -- A -- B -- C -- D -- E -- F -- G -- H -- I -- J -- K -- L -- M -- N -- O -- P -- Q -- R -- S -- T -- U -- V -- W -- Y -- Z.
This well-written, opinionated, and engaging book explains what we can do differently to make serious and sustained progress against cancer--and how we can avoid repeating the policy and practice mistakes of the past.
9781421437644
Medicine-Research-Economic aspects-United States.
Antineoplastic agents-Economic aspects-United States.
Cancer-Chemotherapy-United States.
Electronic books.
KF26 .P737 2020
616.9440610287
Malignant : How Bad Policy and Bad Evidence Harm People with Cancer. - 1st ed. - 1 online resource (304 pages)
Cover -- Half Title -- Title -- Copyright -- Dedication -- Contents -- Acknowledgments -- Introduction -- PART I CANCER DRUGS: The Outcomes They Improve and at What Price -- 1 The Basics of Cancer Drugs: Cost, Benefit, Value -- 2 Surrogate Endpoints in Cancer: What Are They and Where Are They Used? -- 3 The Use and Misuse of Surrogate Endpoints for Drug Approvals -- 4 How High Prices Harm Patients and Society -- PART II SOCIETAL FORCES THAT DISTORT CANCER MEDICINE -- 5 Hype, Spin, and the Unbridled Enthusiasm That Distorts Cancer Medicine -- 6 Financial Conflict of Interest -- 7 The Harms of Financial Conflicts and How to Rehabilitate Medicine -- 8 Will Precision Oncology Save Us? -- PART III HOW TO INTERPRET CANCER EVIDENCE AND TRIALS -- 9 Study Design 201 -- 10 Principles of Oncology Practice -- 11 Important Trials in Oncology -- 12 Global Oncology -- PART IV SOLUTIONS -- 13 How Should Cancer Drug Development Proceed -- 14 What Can Three Federal Agencies Do Tomorrow? -- 15 What Can People with Cancer Do? -- 16 What Can Students, Residents, and Fellows -- Epilogue: The Hallmarks of Successful Cancer Policy -- Glossary -- References -- Index -- A -- B -- C -- D -- E -- F -- G -- H -- I -- J -- K -- L -- M -- N -- O -- P -- Q -- R -- S -- T -- U -- V -- W -- Y -- Z.
This well-written, opinionated, and engaging book explains what we can do differently to make serious and sustained progress against cancer--and how we can avoid repeating the policy and practice mistakes of the past.
9781421437644
Medicine-Research-Economic aspects-United States.
Antineoplastic agents-Economic aspects-United States.
Cancer-Chemotherapy-United States.
Electronic books.
KF26 .P737 2020
616.9440610287